Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 11/20 | 0.55 |
| ▸ | HTR1B | P28222 | 11/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264538 | 0.92 | KDM4E (0.60) | KDM4EATMAPPHTR1DHTR1B | |
| SCHEMBL15576346 | 0.82 | APP (0.65) | KDM4EATMAPPHTR1DHTR1B | |
| SCHEMBL2935082 | 0.81 | HTR1D (0.61) | KDM4EATMAPPHTR1DHTR1B | |
| SCHEMBL4143229 | 0.80 | KDM4E (0.59) | KDM4EATMAPPHTR1DHTR1B | |
| SCHEMBL28794345 | 0.80 | HTR1D (0.55) | KDM4EATMAPPHTR1DHTR1B | |
| SCHEMBL7539016 | 0.79 | HTR1D (0.70) | APPHTR1DHTR1BHTR1AHTR1F | |
| SCHEMBL7477707 | 0.79 | HTR1D (0.64) | APPHTR1DHTR1BHTR1AHTR1F | |
| SCHEMBL2932440 | 0.79 | KDM4E (0.54) | KDM4EATMHTR1DHTR1BHTR1A | |
| SCHEMBL8508032 | 0.77 | KDM4E (0.64) | KDM4EATMAPPHTR1DHTR1B | |
| SCHEMBL1122577 | 0.77 | NOS3 (0.64) | KDM4EATMAPPHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101247853-B | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-12 | — | — | CN | disclosed |
| CN-101910157-B | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2014-05-07 | — | — | CN | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-0666858-B1 | 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT 1) AGONISTS | PFIZER (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1094064-A1 | 5-arylindolederivatives and their use as serotonin(5-ht1)agonists | PFIZER INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| CN-1051313-C | 5-arylindole derivatives | PFIZER (US) | 2000-04-12 | — | — | CN | disclosed |
| EP-0619805-B1 | 5-(HETERO- OR CARBOCYCLYLAMINO)-INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1 AGONISTS | PFIZER (US) | 2000-03-15 | — | — | EP | disclosed |
| CN-1045294-C | Indole derivatives | PFIZER (US) | 1999-09-29 | — | — | CN | disclosed |
| US-5886008-A | 5-arylindole derivatives | PFIZER INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5639752-A | SEROTONIN AGONIST | PFIZER INC (US) | 1997-06-17 | — | — | US | disclosed |
| CN-1094727-A | The 5-(hetero) aryl indole derivatives | PFIZER (US) | 1994-11-09 | — | — | CN | disclosed |
| CN-1072679-A | INDOLE DERIVATIVES | PFIZER (US) | 1993-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | KDM4E 2379/4885ATM 578/4885APP 1127/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | KDM4E 2379/4885ATM 578/4885APP 1127/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | KDM4E 2379/4885ATM 578/4885APP 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.